|
CGI Pharmaceuticals is dedicated to the discovery and development of breakthrough small molecule kinase
inhibitors for a broad range of oncology/angiogenesis and autoimmune/allergic/inflammatory disease indications.
The Company’s fully integrated drug discovery infrastructure comprises proprietary discovery biology and
chemistry, extensive lead generation capabilities, as well as preclinical development expertise.
CGI’s unique approach specifically addresses the major challenges associated with kinase drug discovery
and development. By integrating world-class kinase biology and proprietary chemistry expertise with
efficient ADME/PK and in vivo biology support strategies, CGI has successfully demonstrated that it can
rapidly identify quality kinase inhibitor lead candidates in two high-value and challenging therapeutic
areas. Moreover, CGI has generated a proprietary small molecule kinase inhibitor library of over 50,000
compounds, with demonstrated activity on multiple kinase targets. |
|
